OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to ...

We appreciate the constructive remarks by Chung-Wei Christine Lin and colleagues regarding our systematic review and resulting recommendations.1 Our systematic review and meta-analysis were explicitly ...

The India Gabapentin Market offers opportunities driven by rising neurological disorders, especially among diabetic and aging ...

Chief Executive Officer — Sandy Macrae Chief Development Officer — Nathalie Dubois-Stringfellow Head of Research and Technology — Gregory Davis Principal Financial Officer and Principal Accounting ...

Back pain affects 80 per cent of us at some point, and for many, it’s debilitating. According to NHS figures, back pain is now the leading cause of disability in the UK, responsible for 12 million ...